This morning, Chardan Healthcare Acquisition Corp. (CHACU) filed for a $70 million, Chardan-backed SPAC focusing on Healthcare companies in North America. Chardan Healthcare will be led by senior members of Chardan Capital Markets, a veteran SPAC underwriter.
Gbola Amusa, who has served as Partner, Director of Research, and Head of Healthcare Equity Research at Chardan Capital Markets since December 2014, will be Chairman of the Board for this team and Jonas Grossman, the current Partner and Head of Capital Markets for Chardan, will be leading as President and CEO. Finally, George Kaufman, who is currently Managing Director and Head of Investment Banking, will be CFO and Head of Strategy.
Looking at this SPAC’s structure, these terms look very aggressive. Of the five deals currently on file (CF Finance, Monocle, Schultze, Andina III, Chardan Healthcare), only Chardan Healthcare is offering a 1/2 share in their warrant. AND, it’s the only SPAC on file with a 24 month life. On top of that, the warrant trigger to call the warrants for redemption is set at >$16.00, rather than the standard >$18.00. (We’ll be putting together a comparison of all five, shortly)
Additionally, you will also notice that the underwriting fee is not being split as upfront/deferred. That’s because Chardan has decided to take a flat fee of just $500K, which makes sense since this is their deal and by lowering the underwriting fee, it reduces the amount of at-risk capital needed to bring the trust to 100%. However, they are purchasing their at-risk capital warrants at $0.40.
Since there is a conflict of interest with Chardan Capital Markets underwriting a SPAC with Chardan as a sponsor, Chardan Healthcare will be utilizing B. Riley FBR as their Qualified Independent Underwriter, but again, just like CF Finance, the QIU is not on the cover. That’s branding, folks. Both Chardan and Cantor want their deals to be 100% their own.
It remains to be seen if Chardan Healthcare will stick with these terms given the comparison to the other four SPACs currently on file. It’s aggressive for sure, but it’s a lot easier to start high rather than work your way up from low.
Chardan is sole book-running manager.
Loeb & Loeb LLP and Schiff Hardin LLP are issuer’s counsel and underwriter’s counsel, respectively.
Terms Tracker for the Week Ending May 30, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. May went out with a bang. Four more IPOs priced this week, bringing the monthly tally to 22 and the YTD total to 53. That...
June is set to be one of the quietest months in some time in terms of sponsors and de-SPAC’d companies coming free from their lock-ups, owing to the quieter periods for transactions closing that occurred six and 12 months ago. Up first will be company shareholders for East Asian media conglomerate TNL Mediagene (NASDAQ:TNMG) on...
Pioneer I (NASDAQ:PACHU) has filed for a $220 million SPAC to hunt for a healthcare target with a mix of industry veterans heading up its team. The new SPAC is the 12th new S-1 underwritten by Cantor Fitzgerald this year as left lead as it hopes to join the 10 SPACs that the underwriter has...
At the SPAC of Dawn This week comes to an end with a flurry of SPAC votes including three special meetings called for shareholders to approve business combinations. Aetherium (OTC:GMFI) was also scheduled to seek shareholder approval for its extension proposal, but has punted this vote for two weeks to June 13. Two of today’s...
At the SPAC of Dawn After multiple days of market rallies, traders are set to ingest a full plate of economic indicators today with jobless claims coming first, followed by a GDP growth revisions, home sales and a raft of Fed comments. GDP figures for the first quarter are broadly forecast to be revised downward...